Predicting outcomes for head and neck cancer patients after radiotherapy
Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy Using Multi-parameter Modelling: Disease Control, Toxicity and Quality of Life
This study is testing a new follow-up program for head and neck cancer patients to see if it can reduce side effects from radiation while still being effective in treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Maastricht Radiation Oncology Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Maastricht) |
| Trial ID | NCT01985984 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the quality of radiotherapy for head and neck cancer patients by implementing a Standard Follow-up Program (SFP) that reduces radiation-induced side effects while maintaining treatment efficacy. It focuses on developing accurate outcome prediction models that consider various clinical factors, genomic analyses, and treatment-related parameters. By systematically evaluating the effects of new radiation technologies, the study seeks to enhance personalized medicine approaches for patients with head and neck squamous cell carcinoma.
Who should consider this trial
Good fit: Ideal candidates for this study are patients planned for curatively intended primary or postoperative radiotherapy for head and neck cancer.
Not a fit: Patients who are planned for palliative radiotherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment outcomes and quality of life for head and neck cancer patients undergoing radiotherapy.
How similar studies have performed: Other studies have shown success in using predictive models for cancer treatment outcomes, indicating that this approach has potential for meaningful advancements.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: All patients planned for curatively intended primary or postoperative radiotherapy Exclusion Criteria: All patients planned for palliative radiotherapy
Where this trial is running
Maastricht
- Maastro Clinic — Maastricht, Netherlands (Recruiting)
Study contacts
- Principal investigator: F Hoebers, MD, PhD — Maastro Clinic, The Netherlands
- Study coordinator: F Hoebers, MD, PhD
- Email: frank.hoebers@maastro.nl
- Phone: +31884455666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.